Apollomics was founded as a cross-border company with the vision to become a global leader in the development of novel medicines for cancer patients. We have established a physical presence in Hangzhou, China where our employees and facility are essential to our operations. Our China location will house a state-of-the-art research and development facility that will be crucial as we advance our preclinical and clinical development programs. We also plan to establish manufacturing capabilities to support drug supply for our assets in clinical trials and ultimately for commercialization.
Part of our global strategy has been to include innovation in the East. We have established collaborations with multiple partners in China, and this global presence provides us the opportunity to study our assets in several indications amongst several patient populations. Together with our partners, we are harnessing ongoing research and resources in China and internationally to develop medicines for the rest of the world.